Lexicon Pharmaceuticals (LXRX) Cash & Current Investments (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Cash & Current Investments data on file, last reported at $170.7 million in Q1 2026.

• On a quarterly basis, Cash & Current Investments fell 12.41% year-over-year to $170.7 million in Q1 2026; TTM through Mar 2026 was $170.7 million, a 12.41% decrease from a year earlier, with the FY2025 full-year figure at $96.2 million, down 59.56% from the prior year.
• Cash & Current Investments for Q1 2026 stood at $170.7 million, up from $96.2 million in the prior quarter.
• Over the last five years, Cash & Current Investments for LXRX reached as high as $355.6 million in Q1 2024 and fell as low as $62.0 million in Q2 2022.
• Historically, Cash & Current Investments has averaged $179.6 million across 5 years, with a median of $170.0 million in 2023.
• Across the five-year window, Cash & Current Investments jumped 314.31% in 2023 and plunged 59.56% in 2025, its largest moves.
• Year by year, Cash & Current Investments stood at $138.4 million in 2022, then increased by 22.89% to $170.0 million in 2023, then surged by 39.95% to $238.0 million in 2024, then plunged by 59.56% to $96.2 million in 2025, then jumped by 77.34% to $170.7 million in 2026.
• Per Business Quant data, the three most recent Cash & Current Investments figures were $170.7 million in Q1 2026, $96.2 million in Q4 2025, and $116.0 million in Q3 2025.